Article contents
Evidence-Based Pharmacotherapy of Social Anxiety Disorder
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS1092852900010373/resource/name/firstPage-S1092852900010373a.jpg)
- Type
- Symposium Monograph Supplement
- Information
- Copyright
- Copyright © Cambridge University Press 2005
References
1.Stein, MB, Liebowitz, MR, Lydiard, RB, et al.Paroxetine Treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708–713.CrossRefGoogle ScholarPubMed
2.The Research Unit on Pediatric Psychopharmcology Anxiety Study Group Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;341:1279–1285.Google Scholar
3.Wagner, KD, Berard, R, Stein, MB, et al.A multicenter, randomized, double-blind, placcbo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61:1153–1162.CrossRefGoogle Scholar
4.Versiani, M, Nardi, AE, Figueira, I, et al.Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria. 1997;46:167–171.Google Scholar
5.Davidson, JR, Potts, N, Richichi, E, et al.Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423–428.Google Scholar
6.Gelernter, CS, Uhde, TW, Cimbolic, P, et al.Cognitive behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry. 1991;48:938–945.Google Scholar
7.Blanco, C, Schneier, FR, Schmidt, A, et al.Pharmacological treatment of social anxiety disorders: a meta-analysis. Depress Anxiety. 2003;18:29–40.Google Scholar
8.Stein, MB, Chartiet, MJ, Hazen, AL, et al.Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuations. J Clin Psychopharmcol. 1996;16:218–222.Google Scholar
9.Stein, DJ, Versian, M, Hair, I. et al.Efficacy of paroxetine for relapse prevenrion in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002;59:1111–1118.Google Scholar
10.Walker, JR, Van Ameringen, MA, Swinson, R, et al.Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmcol. 2000;20:636–644.CrossRefGoogle ScholarPubMed
11.Ninan, PT, Papp, L, Dunlop, BW. Relapse prevention study of tiagabine in patients with social anxiety disorder. Poster ptesented at: The 25th Annual Meeting of the Anxiety Disorders Association of America; March 17-20, 2005: Seattle, Washington.Google Scholar
12.Montgomery, S, Durr-Pal, N, Loft, H, et al. Escitalopram prevents relapse in patients suffering from social anxiety disorder (SAD). Poster presented at: The 156th Annual Meeting of the American Psychiartic Association; May 17–22, 2003: San Francisco, California.Google Scholar
13.Stein, DJ, Cameron, A, Amrein, P, et al.Moclobemide is effective and well tolerated in the longterm pharmacotherapy of social anxiety disorder wirh or wirhout comorbid anxiety disorder. Int Clin Psychopharmacol. 2002;17:16l–170.CrossRefGoogle ScholarPubMed
14.Schneier, FR, Blanco, C, Campeas, R, et al.Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety. 2003;17:191–196.CrossRefGoogle ScholarPubMed
15.Randall, CL, Johnson, MR, Thevos, AK, et al.Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14:255–262.Google Scholar
- 2
- Cited by